The Future of Medicine: Access to Gene Therapies
Gene therapy has emerged as a groundbreaking approach to treating once life-threating conditions. This special report from the Blue Cross Blue Shield Association details the science and regulations behind one-time gene therapies, highlighting their potential to revolutionize treatment for rare genetic diseases, provided reasonable financing models are established.
Defects caused by a single gene, known as monogenic disorders, collectively impact nearly 7% to 8% of Americans. As of 2024, the US Food and Drug Administration (FDA) has approved 12 gene therapies aimed at curing a specific defect through a one-time delivery of a therapy. Costs for a single therapy can be as much as $4 million.
This treatment approach is certain to grow with 85 new gene therapies expected to receive FDA approval by 2032 and approximately 10,000 different genetic disorders in need of new treatment options. Annual spending in the United States on these treatments could reach up to $15 billion through the next 10 years.
The surge in gene therapy development underscores the need for a comprehensive understanding of their clinical effectiveness and how to ensure affordable access for all Americans in need of these treatments.
Key Findings
All health care stakeholders have a duty to promote access to these transformative treatments when they are proven to be clinically effective and safe to use.
Blue Cross Blue Shield Association proposes several recommendations to ensure patients can access these therapies while balancing potential benefits and risks:
Key Findings
Centralized Registry: The federal government should assist in the establishment of a database to track health outcomes and negative effects for all gene therapy recipients in the United States.
Key Findings
Benefit Coverage: All stakeholders must collaborate to support innovative payment models and work to educate employers and benefit consultants about these treatments, their potential for long-term societal impact and future cost savings.
Key Findings
Collaboration between payers, manufacturers and FDA: Fostering an early dialogue between these stakeholders will generate relevant evidence and streamline the gap between FDA approval of the treatments and payer coverage.
Conclusion
Gene therapy represents a transformative advancement in health care, offering patients access to potentially curative treatments for previously untreatable genetic conditions.
By addressing the challenges of clinical evidence, health disparities, and affordability, stakeholders can work together to ensure that these innovative therapies are accessible to all who need them.
The latest in health care, delivered.
Subscribe to stay in the know on health care industry news and insights.